Eli Lilly and Company has become a key player in the development and tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce cardiovascular risks. The sophisticated synthesis of tirzepatide requires a series of carefull